Biocardia, Inc. 8-K Filing

FAQ

Key Financial Figures

• $0.001 B — h registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat

Filing Documents

• bcda20251202_8k.htm (8-K) — 57KB
• ex_894853.htm (EX-99.1) — 10KB
• 0001437749-25-036711.txt ( ) — 202KB
• bcda-20251202.xsd (EX-101.SCH) — 3KB
• bcda-20251202_def.xml (EX-101.DEF) — 11KB
• bcda-20251202_lab.xml (EX-101.LAB) — 15KB
• bcda-20251202_pre.xml (EX-101.PRE) — 11KB
• bcda20251202_8k_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On December 2, 2025, the Company held its Annual Meeting. Present at the Annual Meeting in person or by proxy were holders of 5,913,667 shares of the Company's common stock, representing 55.72% of the voting power of the shares of the Company's common stock as of October 8, 2025, the record date for the Annual Meeting, and constituting a quorum for the transaction of business. The matters before the Annual Meeting are described in more detail in the Company's definitive proxy statement filed with the United States Securities and Exchange Commission on November 3, 2025. Proposal 1 – Election of Directors . The following nominees were elected as Class III directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Nominee Votes For Withheld Broker Non-votes Marvin Slosman 3,550,719 198,084 2,164,864 Jay M. Moyes 3,550,555 198,248 2,164,864 Simon H. Stertzer, M.D. 3,557,464 191,339 2,164,864 Proposal 2 – Approval of an amendment, restatement and extension to our 2016 Equity Incentive Plan. The amendment to (i) extend the term of the Restated Plan until October 31, 2035, (ii) change the automatic share reserve increase pursuant to the Restated Plan to automatically increase the number of shares available for issuance under the Restated Plan on the date of this Annual Meeting and the first day of each fiscal year following this Annual Meeting, in an amount equal to, subject to the limitations in the 2016 Plan, four percent (4.0%) of the outstanding shares on the day immediately preceding each automatic increase, and (iii) limit the portion of the share reserve available for issuance pursuant to the exercise of incentive stock options, was approved. Votes For Votes Against Abstentions Broker Non-votes 2,654,280 478,152 616,371 2,164,864 Proposal 3 – Ratification of the Appointment of Independent Regi

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 2, 2025, the BioCardia issued a press release announcing the appointment of Marvin Slosman to its board of directors and the completion of Dr. Richard Krasno's term on the board of directors, a copy of which is furnished as exhibit 99.1 to the Current Report of Form 8-K and is incorporated by reference herein. The information furnished to this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any registration statement of filing under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified in such filing as being incorporated by reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 BioCardia, Inc. press release dated December 3, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: December 3, 2025

View Full Filing

View this 8-K filing on SEC EDGAR